Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
OVAPEX is a unique formula developed by the team of scientists and doctors at Green Milk Concepts
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
